Advertisement

Bone mineral density in women aged 25���35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation

      Abstract

      Introduction

      This 7-year, prospective, matched-cohort, clinical study evaluated the effects of intramuscular depot medroxyprogesterone acetate (DMPA) (150 mg/mL) on bone mineral density (BMD) in women aged 25���35 years.

      Methods

      Bone mineral density changes in new DMPA-IM users (n=248) were compared with those in women using nonhormonal contraception (n=360) for up to 240 weeks of treatment and 96 weeks of posttreatment follow-up (in subjects receiving ���1 dose).

      Results

      At week 240 of treatment, mean percentage changes from baseline in DMPA-IM vs. nonhormonal subjects were: ���5.16% (n=21) vs. +0.19% (n=65), total hip (p<.001); ���5.38% (n=33) vs. +0.43% (n=105), lumbar spine (p<.001). At week 96 posttreatment, these values were: ���0.20% (n=25) vs. +0.84% (n=43), total hip (p=.047); ���1.19% (n=41) vs. +0.47% (n=66), lumbar spine (p=.017).

      Conclusions

      These results show BMD declines during DMPA-IM use; following discontinuation, significant increases in BMD occur through 96 weeks posttreatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Depo-Provera [physician information].
        Pfizer Inc., New York2004
        • Westhoff C.
        Depot-medroxyprogesterone acetate injection (Depo-Provera��): a highly effective contraceptive option with proven long-term safety.
        Contraception. 2003; 68: 75-87
        • Schwallie P.C.
        • Assenzo J.R.
        Contraceptive use ��� efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days.
        Fertil Steril. 1973; 24: 331-339
        • Piccinino L.J.
        • Mosher W.D.
        Trends in contraceptive use in the United States: 1982���1995.
        Fam Plann Perspect. 1998; 30: 4-10
        • Banks E.
        • Berrington A.
        • Casabonne D.
        Overview of the relationship between use of progestogen-only contraceptives and bone mineral density.
        BJOG. 2001; 108: 1214-1221
        • Berenson A.B.
        • Breitkopf C.R.
        • Grady J.J.
        • Rickert V.I.
        • Thomas A.
        Effects of hormonal contraception on bone mineral density after 24 months of use.
        Obstet Gynecol. 2004; 103: 899-906
        • Lara-Torre E.
        • Edwards C.P.
        • Perlman S.
        • Hertweck S.P.
        Bone mineral density in adolescent females using depot medroxyprogesterone acetate.
        J Pediatr Adolesc Gynecol. 2004; 17: 17-21
        • Scholes D.
        • Lacroix A.Z.
        • Ichikawa L.E.
        • Barlow W.E.
        • Ott S.M.
        Injectable hormone contraception and bone density: results from a prospective study.
        Epidemiology. 2002; 13: 581-587
        • Scholes D.
        • Lacroix A.Z.
        • Ichikawa L.E.
        • Barlow W.E.
        • Ott S.M.
        Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
        Arch Pediatr Adolesc Med. 2005; 159: 139-144
        • Petitti D.B.
        • Piaggio G.
        • Mehta S.
        • Cravioto M.C.
        • Meirik O.
        Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population.
        Obstet Gynecol. 2000; 95: 736-744
        • Orr-Walker B.J.
        • Evans M.C.
        • Ames R.W.
        • Clearwater J.M.
        • Cundy T.
        • Reid I.R.
        The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
        Clin Endocrinol (Oxf). 1998; 49: 615-618
        • Cundy T.
        • Cornish J.
        • Roberts H.
        • Elder H.
        • Reid I.R.
        Spinal bone density in women using depot medroxyprogesterone contraception.
        Obstet Gynecol. 1998; 92: 569-573
        • Gbolade B.
        • Ellis S.
        • Murby B.
        • Randall S.
        • Kirkman R.
        Bone density in long term users of depot medroxyprogesterone acetate.
        Br J Obstet Gynaecol. 1998; 105: 790-794
        • Paiva L.C.
        • Pinto-Neto A.M.
        • Faundes A.
        Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
        Contraception. 1998; 58: 351-355
        • Perrotti M.
        • Bahamondes L.
        • Petta C.
        • Castro S.
        Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate.
        Fertil Steril. 2001; 76: 469-473
        • Scholes D.
        • Lacroix A.Z.
        • Ichikawa L.E.
        • Barlow W.E.
        • Ott S.M.
        The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
        Contraception. 2004; 69: 99-104
        • Ryan P.J.
        • Singh S.P.
        • Guillebaud J.
        Depot medroxyprogesterone and bone mineral density.
        J Fam Plann Reprod Health Care. 2002; 28: 12-15
        • Clark M.K.
        • Sowers M.F.R.
        • Nichols S.
        • Levy B.
        Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
        Fertil Steril. 2004; 82: 1580-1586
        • Kalkwarf H.J.
        • Specker B.L.
        Bone mineral loss during lactation and recovery after weaning.
        Obstet Gynecol. 1995; 86: 26-32
        • Polatti F.
        • Capuzzo E.
        • Viazzo F.
        • Colleoni R.
        • Klersy C.
        Bone mineral changes during and after lactation.
        Obstet Gynecol. 1999; 94: 52-56
        • Hayslip C.C.
        • Klein T.A.
        • Wray H.L.
        • Duncan W.E.
        The effects of lactation on bone mineral content in healthy postpartum women.
        Obstet Gynecol. 1989; 73: 588-592
        • Paton L.M.
        • Alexander J.L.
        • Nowson C.A.
        • Frame M.G.
        • Kaymakci B.
        • Wark J.D.
        Pregnancy and lactation have no long-term deleterious effect on measures of bone mineral in healthy women: a twin study.
        Am J Clin Nutr. 2003; 77: 707-714
        • Kojima N.
        • Douchi T.
        • Kosha S.
        • Nagata Y.
        Cross-sectional study of the effects of parturition and lactation on bone mineral density later in life.
        Maturitas. 2002; 41: 203-209
        • Henderson III, P.H.
        • Sowers M.F.
        • Kutzko K.E.
        • Jannausch M.L.
        Bone mineral density in grand multiparous women with extended lactation.
        Am J Obstet Gynecol. 2000; 182: 1371-1377
        • Chantry C.J.
        • Auinger P.
        • Byrd R.S.
        Lactation among adolescent mothers and subsequent bone mineral density.
        Arch Pediatr Adolesc Med. 2004; 158: 650-656
        • Carranza-Lira S.
        • Mera J.P.
        Influence of number of pregnancies and total breast-feeding time on bone mineral density.
        Int J Fertil. 2002; 47: 169-171
        • Kalkwarf H.J.
        • Specker B.L.
        Bone mineral changes during pregnancy and lactation.
        Endocrine. 2002; 17: 49-53
        • Michaelsson K.
        • Baron J.A.
        • Farahmand B.Y.
        • Ljunghall S.
        Influence of parity and lactation on hip fracture risk.
        Am J Epidemiol. 2001; 153: 1166-1172
        • Kalkwarf H.J.
        Hormonal and dietary regulation of changes in bone density during lactation and after weaning in women.
        J Mammary Gland Biol Neoplasia. 1999; 4: 319-329
        • Honda A.
        • Kurabayashi T.
        • Yahata T.
        • Tomita M.
        • Takakuwa K.
        • Tanaka K.
        Lumbar bone mineral density changes during pregnancy and lactation.
        Int J Gynaecol Obstet. 1998; 63: 253-258
        • Kaunitz A.M.
        Injectable contraception. New and existing options.
        Obstet Gynecol Clin North Am. 2000; 27: 741-780
        • Cundy T.
        • Ames R.
        • Horne A.
        • Roberts H.
        • Gamble G.
        • Reid I.R.
        A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate.
        J Clin Endocrinol Metab. 2003; 88: 78-81
        • Cromer B.A.
        • Lazebnik R.
        • Rome E.
        • Bonny A.
        • Ziegler J.
        • Debanne S.M.
        Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception.
        Am J Obstet Gynecol. 2005; 192: 42-47
        • Kaunitz A.M.
        Depo-Provera's black box: time to reconsider?.
        Contraception. 2005; 72: 165-167
        • Hui S.L.
        • Slemenda C.W.
        • Johnston Jr, C.C.
        Age and bone mass as predictors of fracture in a prospective study.
        J Clin Invest. 1988; 81: 1804-1809
        • Kanis J.A.
        • Johnell O.
        • Oden A.
        • Dawson A.
        • De Laet C.
        • Jonsson B.
        Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds.
        Osteoporos Int. 2001; 12: 989-995
        • Templeman C.
        • Boyd H.
        • Hertweck S.P.
        Depomedroxyprogesterone acetate use and weight gain among adolescents.
        J Pediatr Adolesc Gynecol. 2000; 13: 45-46
        • Moore L.L.
        • Valuck R.
        • McDougall C.
        • Fink W.
        A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.
        Contraception. 1995; 52: 215-220
        • Espey E.
        • Steinhart J.
        • Ogburn T.
        • Qualls C.
        Depo-Provera associated with weight gain in Navajo women.
        Contraception. 2000; 62: 55-58
        • Mangan S.A.
        • Larsen P.G.
        • Hudson S.
        Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate.
        J Pediatr Adolesc Gynecol. 2002; 15: 79-82
        • Danli S.
        • Qingxiang S.
        • Guowei S.
        A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women.
        Contraception. 2000; 62: 15-18
        • Risser W.L.
        • Gefter L.R.
        • Barratt M.S.
        • Risser J.M.H.
        Weight change in adolescents who used hormonal contraception.
        J Adolesc Health. 1999; 24: 433-436
        • Pelkman C.L.
        • Chow M.
        • Heinbach R.A.
        • Rolls B.J.
        Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women.
        Am J Clin Nutr. 2001; 73: 19-26
        • Deslypere J.P.
        • Thiery M.
        • Vermeulen A.
        Effect of long-term hormonal contraception on plasma lipids.
        Contraception. 1985; 31: 633-642
        • Fajumi J.O.
        Alterations in blood lipids and side effects induced by Depo-Provera in Nigerian women.
        Contraception. 1983; 27: 161-175
        • Liew D.F.M.
        • Ng C.S.A.
        • Yong Y.M.
        • Ratnam S.S.
        Long-term effects of Depo-Provera on carbohydrate and lipid metabolism.
        Contraception. 1985; 31: 51-64
        • Enk L.
        • Landgren B.-M.
        • Lindberg U.-B.
        • Silfverstolpe G.
        • Crona N.
        A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
        Horm Metab Res. 1992; 24: 85-89
        • Fahmy K.
        • Khairy M.
        • Allam G.
        • Gobran F.
        • Alloush M.
        Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women.
        Contraception. 1991; 44: 431-444
        • Garza-Flores J.
        • De la Cruz D.L.
        • Valles de Bourges V.
        • Martinez M.
        • Fuziwara J.L.
        • Perez-Palacios G.
        Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
        Contraception. 1991; 44: 61-71
        • Kremer J.
        • de Bruijn H.W.A.
        • Hindriks F.R.
        Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate.
        Contraception. 1980; 22: 359-367
        • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
        Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study.
        Contraception. 1998; 57: 315-324
        • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
        Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study.
        Lancet. 1997; 349: 1202-1209
        • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
        Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.
        Lancet. 1995; 346: 1575-1582
        • American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. The use of hormonal contraception in women with coexisting medical conditions
        Int J Gynaecol Obstet. 2001; 75: 93-106